{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:29:25Z","timestamp":1792250965059,"version":"4.4.0"},"reference-count":354,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune diseases arise from atypical immune responses that attack self-tissue epitopes, and their development is intricately connected to the disruption of the JAK-STAT signaling pathway, where SOCS proteins play crucial roles. Conditions such as autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis exhibit immune system dysfunctions associated with JAK-STAT signaling dysregulation. Emerging therapeutic strategies utilize JAK-STAT inhibitors and SOCS mimetics to modulate immune responses and alleviate autoimmune manifestations. Although more research and clinical studies are required to assess their effectiveness, safety profiles, and potential for personalized therapeutic approaches in autoimmune conditions, JAK-STAT inhibitors and SOCS mimetics show promise as potential treatment options. This review explores the action, effectiveness, safety profiles, and future prospects of JAK inhibitors and SOCS mimetics as therapeutic agents for psoriasis, autoimmune uveitis, systemic lupus erythematosus, and autoimmune encephalitis. The findings underscore the importance of investigating these targeted therapies to advance treatment options for individuals suffering from autoimmune diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1271102","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T18:17:18Z","timestamp":1698344238000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis"],"prefix":"10.3389","volume":"14","author":[{"given":"Rahul","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bakay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakon","family":"Hakonarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098224","article-title":"CLEC16A-an emerging master regulator of autoimmunity and neurodegeneration","volume":"24","author":"Pandey","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"103313","DOI":"10.1016\/j.autrev.2023.103313","article-title":"Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome","volume":"22","author":"Kapoor","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/nu13113956","article-title":"How to tackle the relationship between autoimmune diseases and diet: well begun is half-done","volume":"13","author":"Mazzucca","year":"2021","journal-title":"Nutrients"},{"key":"B4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1120281","article-title":"Editorial: JAK inhibition in autoimmune and inflammatory diseases","volume":"13","author":"Telliez","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"120516","DOI":"10.1016\/j.lfs.2022.120516","article-title":"Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis","volume":"298","author":"Srivastava","year":"2022","journal-title":"Life Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.9.1327","article-title":"New developments in IL-6 dependent biology and therapy: where do we stand and what are the options","volume":"8","author":"Kallen","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(02)00319-1","article-title":"The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R\/IL-6 complex","volume":"1592","author":"Jones","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S400871","article-title":"The role of IL-6 and TMEM100 in lumbar discogenic pain and the mechanism of the glycine-serine-threonine metabolic axis: A metabolomic and molecular biology study","volume":"16","author":"Guo","year":"2023","journal-title":"J Pain Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cytogfr.2015.07.002","article-title":"Systems biology of IL-6, IL-12 family cytokines","volume":"26","author":"Dittrich","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.4.11.2199284","article-title":"Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF)","volume":"4","author":"Akira","year":"1990","journal-title":"FASEB J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0091","article-title":"Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF","volume":"112","author":"Martinez-Moczygemba","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1140-4639(05)80052-8","article-title":"[Biology and clinical applications of the principal hematopoietic cytokines (GM-CSF, G-CSF, IL-3, IL-6, IL-1)]","volume":"33","author":"Deconinck","year":"1990","journal-title":"Rev Fr Transfus Hemobiol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210115","article-title":"Immunomodulatory role of interferons in viral and bacterial infections","volume":"24","author":"Mertowska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ai.2019.11.001","article-title":"Deciphering the pathways to antiviral innate immunity and inflammation","volume":"145","author":"Yang","year":"2020","journal-title":"Adv Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.022","article-title":"The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases","volume":"147","author":"Damsky","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12944-022-01693-z","article-title":"Hypoxia-induced MIF induces dysregulation of lipid metabolism in Hep2 laryngocarcinoma through the IL-6\/JAK-STAT pathway","volume":"21","author":"Yang","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1097\/MAO.0000000000002850","article-title":"JAK\/STAT dysregulation with SOCS1 overexpression in acquired cholesteatoma-adjacent mucosa","volume":"42","author":"Westerberg","year":"2021","journal-title":"Otol Neurotol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2050-7771-1-5","article-title":"Dysregulation of JAK-STAT pathway in hematological Malignancies and JAK inhibitors for clinical application","volume":"1","author":"Furqan","year":"2013","journal-title":"biomark Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0843-1","article-title":"Epigenetic dysregulation of the Jak\/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias","volume":"83","author":"Chim","year":"2004","journal-title":"Ann Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.semcdb.2014.03.023","article-title":"JAK\/STAT pathway dysregulation in tumors: a Drosophila perspective","volume":"28","author":"Amoyel","year":"2014","journal-title":"Semin Cell Dev Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036350","article-title":"Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors","volume":"96","author":"Hornakova","year":"2011","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.163790","article-title":"Ruxolitinib, a potent JAK1\/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia","volume":"102","author":"Gunawan","year":"2017","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055607","article-title":"Case Report: Mutations in JAK3 causing severe combined immunodeficiency complicated by disseminated Bacille Calmette-Guerin disease and Pneumocystis pneumonia","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.04.014","article-title":"Jak3 and the pathogenesis of severe combined immunodeficiency","volume":"41","author":"O\u2019Shea","year":"2004","journal-title":"Mol Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2687","article-title":"In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction","volume":"183","author":"Candotti","year":"1996","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1998.tb08990.x","article-title":"Molecular and biochemical characterization of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: implications for treatment","volume":"102","author":"Bozzi","year":"1998","journal-title":"Br J Haematol"},{"key":"B33","article-title":"Common variable immunodeficiency or late-onset combined immunodeficiency: A new hypomorphic JAK3 patient and review of the literature","volume":"25","author":"Abolhassani","year":"2015","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/4.9.1693","article-title":"Intronic point mutation in the IL2RG gene causing X-linked severe combined immunodeficiency","volume":"4","author":"Tassara","year":"1995","journal-title":"Hum Mol Genet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00251-016-0949-3","article-title":"A novel deletion mutation in IL2RG gene results in X-linked severe combined immunodeficiency with an atypical phenotype","volume":"69","author":"Mou","year":"2017","journal-title":"Immunogenetics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/genes13010035","article-title":"Somatic reversion of a novel IL2RG mutation resulting in atypical X-linked combined immunodeficiency","volume":"13","author":"Hou","year":"2021","journal-title":"Genes (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02065.x","article-title":"Human immunodeficiency virus-1 envelope glycoproteins and anti-CD4 antibodies inhibit interleukin-2-induced Jak\/STAT signalling in human CD4 T lymphocytes","volume":"131","author":"Kryworuchko","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-007-0045-8","article-title":"Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity","volume":"38","author":"Holland","year":"2007","journal-title":"Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.mce.2017.01.035","article-title":"JAK\/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs","volume":"451","author":"Cornez","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0352","article-title":"Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves\u2019 hyperthyroidism","volume":"145","author":"Land","year":"2004","journal-title":"Endocrinology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1183\/09031936.04.00043104","article-title":"Autoimmunity, T-cells and STAT-4 in the pathogenesis of chronic obstructive pulmonary disease","volume":"24","author":"Cosio","year":"2004","journal-title":"Eur Respir J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.821","article-title":"STAT3 mutation-associated airway epithelial defects in Job syndrome","volume":"152","author":"Zhang","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc076367","article-title":"STAT3 mutation in the original patient with Job\u2019s syndrome","volume":"357","author":"Renner","year":"2007","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0323","article-title":"JAK: not just another kinase","volume":"21","author":"Agashe","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cyto.2016.06.017","article-title":"JAK-STAT signaling in cancer: From cytokines to non-coding genome","volume":"87","author":"Pencik","year":"2016","journal-title":"Cytokine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2007.12.002","article-title":"Mining for JAK-STAT mutations in cancer","volume":"33","author":"Constantinescu","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071971","article-title":"JAK-STAT signalling pathway in cancer","volume":"12","author":"Brooks","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07281.x","article-title":"A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors","volume":"14","author":"Yoshimura","year":"1995","journal-title":"EMBO J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/43213","article-title":"A new protein containing an SH2 domain that inhibits JAK kinases","volume":"387","author":"Endo","year":"1997","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/43206","article-title":"A family of cytokine-inducible inhibitors of signalling","volume":"387","author":"Starr","year":"1997","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients","volume":"81","author":"Hoftberger","year":"2013","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","author":"Naka","year":"1997","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/molbev\/msy230","article-title":"Insights into the evolution of the suppressors of cytokine signaling (SOCS) gene family in vertebrates","volume":"36","author":"Wang","year":"2019","journal-title":"Mol Biol Evol"},{"key":"B54","article-title":"[Expression of suppressor of cytokine signaling in retina of experimental autoimmune uveoretinitis]","volume":"44","author":"Wang","year":"2008","journal-title":"Zhonghua Yan Ke Za Zhi."},{"key":"B55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1744-313X.2006.00563.x","article-title":"Association study of polymorphisms in SOCS family genes with type 1 diabetes mellitus","volume":"33","author":"Ni","year":"2006","journal-title":"Int J Immunogenet."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010218","article-title":"Differential transcription of SOCS5 and SOCS7 in multiple sclerosis patients treated with interferon beta or glatiramer acetate","volume":"21","author":"Rojas-Morales","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bbrc.2022.01.097","article-title":"Inhibition of microRNA-448 suppresses CD4(+) T cell inflammatory activation via up-regulating suppressor of cytokine signaling 5 in systemic lupus erythematosus","volume":"596","author":"Zhang","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01934","article-title":"Mechanisms of M2 macrophage-derived exosomal long non-coding RNA PVT1 in regulating th17 cell response in experimental autoimmune encephalomyelitisa","volume":"11","author":"Wu","year":"2020","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.073726","article-title":"SOCS-6 negatively regulates T cell activation through targeting p56lck to proteasomal degradation","volume":"285","author":"Choi","year":"2010","journal-title":"J Biol Chem"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2017.12.003","article-title":"Suppressor of cytokine signaling 6 can enhance epidermal growth factor receptor signaling pathway in Bombyx mori (Dazao)","volume":"81","author":"Abbas","year":"2018","journal-title":"Dev Comp Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41419-020-03014-7","article-title":"PTPN14 aggravates inflammation through promoting proteasomal degradation of SOCS7 in acute liver failure","volume":"11","author":"Fu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.14288","article-title":"Differentiated expressed miRNAs in splenic monocyte induced by burn injury in mice","author":"Liu","year":"2023","journal-title":"Int Wound J"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.727987","article-title":"SOCS proteins in immunity, inflammatory diseases, and immune-related cancer","volume":"8","author":"Sobah","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2017.03.023","article-title":"Selective targeting of SH2 domain-phosphotyrosine interactions of Src family tyrosine kinases with monobodies","volume":"429","author":"Kukenshoner","year":"2017","journal-title":"J Mol Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.03.024","article-title":"The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability","volume":"22","author":"Babon","year":"2006","journal-title":"Mol Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1252404","article-title":"VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases","volume":"18","author":"Kamura","year":"2004","journal-title":"Genes Dev"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.01.024","article-title":"The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression","volume":"387","author":"Babon","year":"2009","journal-title":"J Mol Biol"},{"key":"B68","first-page":"1","article-title":"SOCS proteins in development and disease","volume":"2","author":"Trengove","year":"2013","journal-title":"Am J Clin Exp Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/prot.23252","article-title":"The N-terminal domains of SOCS proteins: a conserved region in the disordered N-termini of SOCS4 and 5","volume":"80","author":"Feng","year":"2012","journal-title":"Proteins"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e0162111","DOI":"10.1371\/journal.pone.0162111","article-title":"Rapid inflammation in mice lacking both SOCS1 and SOCS3 in hematopoietic cells","volume":"11","author":"Ushiki","year":"2016","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxab055","article-title":"SOCS: negative regulators of cytokine signaling for immune tolerance","volume":"33","author":"Yoshimura","year":"2021","journal-title":"Int Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1011","article-title":"The SOCS box-adapting proteins for ubiquitination and proteasomal degradation","volume":"64","author":"Linossi","year":"2012","journal-title":"IUBMB Life"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(02)02085-6","article-title":"The SOCS box: a tale of destruction and degradation","volume":"27","author":"Kile","year":"2002","journal-title":"Trends Biochem Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5414.657","article-title":"Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase","volume":"284","author":"Kamura","year":"1999","journal-title":"Science"},{"key":"B75","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/brain\/awu310","article-title":"Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice","volume":"138","author":"Planaguma","year":"2015","journal-title":"Brain"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1619-y","article-title":"SOCS proteins in regulation of receptor tyrosine kinase signaling","volume":"71","author":"Kazi","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.08.006","article-title":"The many faces of the SOCS box","volume":"19","author":"Piessevaux","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.12.004","article-title":"Inhibition of IL-6 family cytokines by SOCS3","volume":"26","author":"Babon","year":"2014","journal-title":"Semin Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-170597","article-title":"Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus","volume":"25","author":"Strebovsky","year":"2011","journal-title":"FASEB J"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.8018","article-title":"SOCS1 regulates the IFN but not NFkappaB pathway in TLR-stimulated human monocytes and macrophages","volume":"181","author":"Prele","year":"2008","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"198748","DOI":"10.1016\/j.virusres.2022.198748","article-title":"Suppressor of cytokine signaling 1 (SOCS1) inhibits antiviral responses to facilitate Senecavirus A infection by regulating the NF-kappaB signaling pathway","volume":"313","author":"Chen","year":"2022","journal-title":"Virus Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"106442","DOI":"10.1016\/j.isci.2023.106442","article-title":"SOCS1 regulates a subset of NFkappaB-target genes through direct chromatin binding and defines macrophage functional phenotypes","volume":"26","author":"Coelho","year":"2023","journal-title":"iScience"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e46082","DOI":"10.1371\/journal.pone.0046082","article-title":"MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1","volume":"7","author":"Yao","year":"2012","journal-title":"PloS One"},{"key":"B85","doi-asserted-by":"publisher","first-page":"8060182","DOI":"10.1155\/2016\/8060182","article-title":"miR-155 regulated inflammation response by the SOCS1-STAT3-PDCD4 axis in atherogenesis","volume":"2016","author":"Ye","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B86","doi-asserted-by":"publisher","first-page":"154827","DOI":"10.1016\/j.phymed.2023.154827","article-title":"Total saponins from Panax japonicus reduce inflammation in adipocytes through the miR155\/SOCS1\/NFkappaB signaling pathway","volume":"115","author":"Gao","year":"2023","journal-title":"Phytomedicine"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502240","article-title":"IL-10-induced miR-155 targets SOCS1 to enhance IgE-mediated mast cell function","volume":"196","author":"Qayum","year":"2016","journal-title":"J Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2567.2011.03514.x","article-title":"miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production","volume":"135","author":"Cardoso","year":"2012","journal-title":"Immunology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.5607\/en.2014.23.2.148","article-title":"Suppression of miR-155 expression in IFN-gamma-treated astrocytes and microglia by DJ-1: A possible mechanism for maintaining SOCS1 expression","volume":"23","author":"Kim","year":"2014","journal-title":"Exp Neurobiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"156248","DOI":"10.1016\/j.cyto.2023.156248","article-title":"SARS-CoV2 infection induce miR-155 expression and skewed Th17\/Treg balance by changing SOCS1 level: A clinical study","volume":"169","author":"Soltani-Zangbar","year":"2023","journal-title":"Cytokine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v21i1.8608","article-title":"Altered expression levels of microRNA-155 and SOCS-1 in peripheral blood mononuclear cells of newly diagnosed breast cancer patients","volume":"21","author":"Iranparast","year":"2022","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9786-2","article-title":"SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155","volume":"30","author":"di Iasio","year":"2012","journal-title":"Invest New Drugs"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2576","article-title":"Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1","volume":"30","author":"Huang","year":"2013","journal-title":"Oncol Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.01.015","article-title":"Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers","volume":"82","author":"Mignacca","year":"2016","journal-title":"Cytokine"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201811_16269","article-title":"MiR-155 promotes the proliferation and migration of breast cancer cells via targeting SOCS1 and MMP16","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.06.041","article-title":"v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells","volume":"15","author":"Limnander","year":"2004","journal-title":"Mol Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.042035699","article-title":"Pim serine\/threonine kinases regulate the stability of Socs-1 protein","volume":"99","author":"Chen","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.221","article-title":"JAB\/SOCS1\/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling","volume":"97","author":"Sporri","year":"2001","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.434","article-title":"Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1","volume":"169","author":"Federici","year":"2002","journal-title":"J Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303021200","article-title":"Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells","volume":"278","author":"Cornish","year":"2003","journal-title":"J Biol Chem"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1383","article-title":"Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses","volume":"170","author":"Ding","year":"2003","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0104041","article-title":"Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling","volume":"76","author":"van de Geijn","year":"2004","journal-title":"J Leukoc Biol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nature06010","article-title":"A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene","volume":"448","author":"Hakonarson","year":"2007","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2010.59","article-title":"Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus","volume":"12","author":"Mero","year":"2011","journal-title":"Genes Immun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr250","article-title":"Interrogating the complex role of chromosome 16p13.13 in multiple sclerosis susceptibility: independent genetic signals in the CIITA-CLEC16A-SOCS1 gene complex","volume":"20","author":"Zuvich","year":"2011","journal-title":"Hum Mol Genet"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-020-18925-4","article-title":"Early-onset autoimmunity associated with SOCS1 haploinsufficiency","volume":"11","author":"Hadjadj","year":"2020","journal-title":"Nat Commun"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01292","article-title":"Defective suppressor of cytokine signaling 1 signaling contributes to the pathogenesis of systemic lupus erythematosus","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00324","article-title":"Therapeutic implication of SOCS1 modulation in the treatment of autoimmunity and cancer","volume":"10","author":"Sharma","year":"2019","journal-title":"Front Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00024382-200202000-00001","article-title":"Suppressors of cytokine signaling (SOCS): inhibitors of the JAK\/STAT pathway","volume":"17","author":"Cooney","year":"2002","journal-title":"Shock"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2012.52","article-title":"Multiple sclerosis-associated single-nucleotide polymorphisms in CLEC16A correlate with reduced SOCS1 and DEXI expression in the thymus","volume":"14","author":"Leikfoss","year":"2013","journal-title":"Genes Immun"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.2.616","article-title":"Thyrotropin-mediated repression of class II trans-activator expression in thyroid cells: involvement of STAT3 and suppressor of cytokine signaling","volume":"171","author":"Kim","year":"2003","journal-title":"J Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.97.016","article-title":"SPRED, and NR4a: Negative regulators of cytokine signaling and transcription in immune tolerance","volume":"97","author":"Yoshimura","year":"2021","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.02.005","article-title":"Expression of suppressor of cytokine signaling 1 (SOCS1) gene dramatically increases in relapsing-remitting multiple sclerosis","volume":"350","author":"Pahlevan Kakhki","year":"2015","journal-title":"J Neurol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","author":"Burton","year":"2007","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0718","article-title":"Association of type 1 diabetes with two Loci on 12q13 and 16p13 and the influence coexisting thyroid autoimmunity in Japanese","volume":"94","author":"Awata","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/ng.381","article-title":"Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes","volume":"41","author":"Barrett","year":"2009","journal-title":"Nat Genet"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/ng.249","article-title":"Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci","volume":"40","author":"Cooper","year":"2008","journal-title":"Nat Genet"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0364","article-title":"Genetic analysis of adult-onset autoimmune diabetes","volume":"60","author":"Howson","year":"2011","journal-title":"Diabetes"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.098376","article-title":"Chromosomal region 16p13: further evidence of increased predisposition to immune diseases","volume":"69","author":"Martinez","year":"2010","journal-title":"Ann rheumatic diseases."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3245","article-title":"Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers","volume":"47","author":"Onengut-Gumuscu","year":"2015","journal-title":"Nat Genet"},{"key":"B121","doi-asserted-by":"publisher","first-page":"245384","DOI":"10.1155\/2012\/245384","article-title":"The correlation between the CLEC16A gene and genetic susceptibility to type 1 diabetes in Chinese children","volume":"2012","author":"Sang","year":"2012","journal-title":"Int J Endocrinol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/ng2068","article-title":"Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes","volume":"39","author":"Todd","year":"2007","journal-title":"Nat Genet"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03437.x","article-title":"Intron polymorphism in the KIAA0350 gene is reproducibly associated with susceptibility to type 1 diabetes (T1D) in the Han Chinese population","volume":"71","author":"Wu","year":"2009","journal-title":"Clin endocrinology."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1234","article-title":"Analysis of the HLA and non-HLA susceptibility loci in Japanese type 1 diabetes","volume":"27","author":"Yamashita","year":"2011","journal-title":"Diabetes\/metabolism Res Rev"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2008.84","article-title":"Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia","volume":"10","author":"Zoledziewska","year":"2009","journal-title":"Genes Immun"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e1002216","DOI":"10.1371\/journal.pgen.1002216","article-title":"Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases","volume":"7","author":"Plagnol","year":"2011","journal-title":"PloS Genet"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the cytokine BAFF and autoimmunity risk","volume":"376","author":"Steri","year":"2017","journal-title":"N Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.81","article-title":"Multiple sclerosis susceptibility alleles in African Americans","volume":"11","author":"Johnson","year":"2010","journal-title":"Genes Immun"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2008.83","article-title":"International Multiple Sclerosis Genetics C. The expanding genetic overlap between multiple sclerosis and type I diabetes","volume":"10","author":"Booth","year":"2009","journal-title":"Genes Immun"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/ng.401","article-title":"Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci","volume":"41","author":"De Jager","year":"2009","journal-title":"Nat Genet"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a92c25","article-title":"Risk alleles for multiple sclerosis in multiplex families","volume":"72","author":"D\u2019Netto","year":"2009","journal-title":"Neurology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2770","article-title":"Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis","volume":"45","author":"Beecham","year":"2013","journal-title":"Nat Genet"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1501678","article-title":"Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation","volume":"2","author":"Andlauer","year":"2016","journal-title":"Sci Adv"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510384011","article-title":"Evaluation of the established non-MHC multiple sclerosis loci in an Indian population","volume":"17","author":"Pandit","year":"2011","journal-title":"Mult Scler."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2009.03.010","article-title":"Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus","volume":"211","author":"Perera","year":"2009","journal-title":"J Neuroimmunol."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2008.59","article-title":"Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians","volume":"9","author":"Rubio","year":"2008","journal-title":"Genes Immun"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073493","article-title":"Risk alleles for multiple sclerosis identified by a genomewide study","volume":"357","author":"Hafler","year":"2007","journal-title":"New Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2009.96","article-title":"Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis","volume":"54","author":"Hoppenbrouwers","year":"2009","journal-title":"J Hum Genet"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01421.x","article-title":"More CLEC16A gene variants associated with multiple sclerosis","volume":"123","author":"Nischwitz","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"8395","DOI":"10.1038\/s41598-018-26842-2","article-title":"Common genetic variation in the autoimmune regulator (AIRE) locus is associated with autoimmune Addison\u2019s disease in Sweden","volume":"8","author":"Eriksson","year":"2018","journal-title":"Sci Rep"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0821","article-title":"Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency","volume":"93","author":"Skinningsrud","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B143","doi-asserted-by":"publisher","first-page":"16021","DOI":"10.1038\/ncomms16021","article-title":"Transancestral mapping and genetic load in systemic lupus erythematosus","volume":"8","author":"Langefeld","year":"2017","journal-title":"Nat Commun"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3603","article-title":"Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus","volume":"48","author":"Morris","year":"2016","journal-title":"Nat Genet"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3434","article-title":"Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus","volume":"47","author":"Bentham","year":"2015","journal-title":"Nat Genet"},{"key":"B146","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ajhg.2012.11.018","article-title":"Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians","volume":"92","author":"Yang","year":"2013","journal-title":"Am J Hum Genet"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2009.50","article-title":"Specific association of a CLEC16A\/KIAA0350 polymorphism with NOD2\/CARD15(-) Crohn\u2019s disease patients","volume":"17","author":"Marquez","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3675","article-title":"Common variants at PVT1, ATG13-AMBRA1, AHI1 and CLEC16A are associated with selective IgA deficiency","volume":"48","author":"Bronson","year":"2016","journal-title":"Nat Genet"},{"key":"B149","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1038\/ncomms6966","article-title":"Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci","volume":"6","author":"Betz","year":"2015","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.129","article-title":"Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance","volume":"132","author":"Jagielska","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114934","article-title":"A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis","volume":"69","author":"Skinningsrud","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B152","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1038\/ncomms9019","article-title":"International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways","volume":"6","author":"Cordell","year":"2015","journal-title":"Nat Commun"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2395","article-title":"Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis","volume":"44","author":"Liu","year":"2012","journal-title":"Nat Genet"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.89","article-title":"Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes","volume":"13","author":"Hirschfield","year":"2012","journal-title":"Genes Immun"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/ng.789","article-title":"Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis","volume":"43","author":"Mells","year":"2011","journal-title":"Nat Genet"},{"key":"B156","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s42003-021-02227-6","article-title":"Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank","volume":"4","author":"Valette","year":"2021","journal-title":"Commun Biol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2213-2600(18)30389-8","article-title":"Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study","volume":"7","author":"Shrine","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30055-4","article-title":"Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies","volume":"7","author":"Pividori","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0121-0","article-title":"A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases","volume":"50","author":"Zhu","year":"2018","journal-title":"Nat Genet"},{"key":"B160","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41588-017-0014-7","article-title":"Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks","volume":"50","author":"Demenais","year":"2018","journal-title":"Nat Genet"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0861OC","article-title":"Identification of four novel loci in asthma in European American and African American populations","volume":"195","author":"Almoguera","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3570","article-title":"Detection and interpretation of shared genetic influences on 42 human traits","volume":"48","author":"Pickrell","year":"2016","journal-title":"Nat Genet"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1053761","article-title":"CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population","volume":"13","author":"Niu","year":"2022","journal-title":"Front Genet"},{"key":"B164","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13223-020-0411-9","article-title":"Replication study of susceptibility variants associated with allergic rhinitis and allergy in Han Chinese","volume":"16","author":"Gao","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1534\/g3.114.010926","article-title":"Polymorphisms of CLEC16A region and autoimmune thyroid diseases","volume":"4","author":"Muhali","year":"2014","journal-title":"G3 (Bethesda)"},{"key":"B166","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1038\/ncomms7804","article-title":"Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-018-0034-z","article-title":"Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis","volume":"20","author":"Kottyan","year":"2019","journal-title":"Genes Immun"},{"key":"B168","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ng.543","article-title":"Multiple common variants for celiac disease influencing immune gene expression","volume":"42","author":"Dubois","year":"2010","journal-title":"Nat Genet"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189498","article-title":"Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations","volume":"13","author":"Gorlova","year":"2018","journal-title":"PloS One"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.651971","article-title":"Immune system and neuroinflammation in idiopathic parkinson\u2019s disease: association analysis of genetic variants and miRNAs interactions","volume":"12","author":"Strafella","year":"2021","journal-title":"Front Genet"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.856493","article-title":"Autoimmune disease associated CLEC16A variants convey risk of parkinson\u2019s disease in Han Chinese","volume":"13","author":"Fan","year":"2022","journal-title":"Front Genet"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B173","doi-asserted-by":"publisher","first-page":"2040622321993442","DOI":"10.1177\/2040622321993442","article-title":"Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges","volume":"12","author":"He","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"B174","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13073-021-00853-7","article-title":"Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis","volume":"13","author":"Plichta","year":"2021","journal-title":"Genome Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"7372","DOI":"10.1038\/s41598-021-86493-8","article-title":"JAK\/STAT inhibitor therapy partially rescues the lipodystrophic autoimmune phenotype in Clec16a KO mice","volume":"11","author":"Pandey","year":"2021","journal-title":"Sci Rep"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2017.02.017","article-title":"Human CLEC16A regulates autophagy through modulating mTOR activity","volume":"352","author":"Tam","year":"2017","journal-title":"Exp Cell Res"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120320109","article-title":"Drosophila Golgi membrane protein Ema promotes autophagosomal growth and function","volume":"109","author":"Kim","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.05.016","article-title":"The diabetes susceptibility gene Clec16a regulates mitophagy","volume":"157","author":"Soleimanpour","year":"2014","journal-title":"Cell"},{"key":"B179","doi-asserted-by":"publisher","first-page":"9319","DOI":"10.1038\/s41598-021-88895-0","article-title":"Inducible knockout of Clec16a in mice results in sensory neurodegeneration","volume":"11","author":"Hain","year":"2021","journal-title":"Sci Rep"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-022-02511-3","article-title":"CLEC16A interacts with retromer and TRIM27, and its loss impairs endosomal trafficking and neurodevelopment","volume":"142","author":"Smits","year":"2023","journal-title":"Hum Genet"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00183","article-title":"SOCS1 mimetics and antagonists: A complementary approach to positive and negative regulation of immune function","volume":"6","author":"Ahmed","year":"2015","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-023-03486-0","article-title":"Strategies to improve the physicochemical properties of peptide-based drugs","volume":"40","author":"Lee","year":"2023","journal-title":"Pharm Res"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7510","article-title":"Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function","volume":"172","author":"Flowers","year":"2004","journal-title":"J Immunol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5058","article-title":"Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist","volume":"178","author":"Waiboci","year":"2007","journal-title":"J Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.10.018","article-title":"The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis","volume":"232","author":"Jager","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"2939370","DOI":"10.1155\/2016\/2939370","article-title":"SOCS1 mimetic peptide suppresses chronic intraocular inflammatory disease (Uveitis)","volume":"2016","author":"He","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B187","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.exer.2018.07.020","article-title":"A cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis","volume":"177","author":"Ahmed","year":"2018","journal-title":"Exp Eye Res"},{"key":"B188","doi-asserted-by":"publisher","first-page":"ra37","DOI":"10.1126\/scisignal.1162191","article-title":"Intracellular delivery of a cell-penetrating SOCS1 that targets IFN-gamma signaling","volume":"2","author":"DiGiandomenico","year":"2009","journal-title":"Sci Signal"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.095216","article-title":"Extended anti-inflammatory action of a degradation-resistant mutant of cell-penetrating suppressor of cytokine signaling 3","volume":"285","author":"Fletcher","year":"2010","journal-title":"J Biol Chem"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24134","article-title":"Therapeutic targeting of STAT pathways in CNS autoimmune diseases","volume":"2","author":"Egwuagu","year":"2013","journal-title":"JAKSTAT"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.05.011","article-title":"Topical administration of a suppressor of cytokine signaling-1 (SOCS1) mimetic peptide inhibits ocular inflammation and mitigates ocular pathology during mouse uveitis","volume":"62","author":"He","year":"2015","journal-title":"J Autoimmun"},{"key":"B192","doi-asserted-by":"publisher","first-page":"7177","DOI":"10.1038\/s41598-022-11338-x","article-title":"Open label safety and efficacy pilot to study mitigation of equine recurrent uveitis through topical suppressor of cytokine signaling-1 mimetic peptide","volume":"12","author":"Plummer","year":"2022","journal-title":"Sci Rep"},{"key":"B193","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1038\/s41598-021-86017-4","article-title":"Suppressor of cytokine signaling-1 mimetic peptides attenuate lymphocyte activation in the MRL\/lpr mouse autoimmune model","volume":"11","author":"Sharma","year":"2021","journal-title":"Sci Rep"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343370","article-title":"Therapeutical potential of a peptide mimicking the SOCS1 kinase inhibitory region in skin immune responses","volume":"43","author":"Madonna","year":"2013","journal-title":"Eur J Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2519","article-title":"SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition","volume":"20","author":"Kershaw","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15629","article-title":"SOCS3 inhibits the pathological effects of IL-22 in non-melanoma skin tumor-derived keratinocytes","volume":"8","author":"Madonna","year":"2017","journal-title":"Oncotarget"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42440","article-title":"A look at autoimmunity and inflammation in the eye","volume":"120","author":"Caspi","year":"2010","journal-title":"J Clin Invest."},{"key":"B198","article-title":"Immunogenetic aspects of clinical and experimental uveitis","volume":"4","author":"Caspi","year":"1992","journal-title":"Reg Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.02.003","article-title":"The immunopathogenesis of chronic and relapsing autoimmune uveitis - Lessons from experimental rat models","volume":"65","author":"Diedrichs-Mohring","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.06.004","article-title":"New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review","volume":"49","author":"Rosenbaum","year":"2019","journal-title":"Semin Arthritis Rheumatol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cimid.2015.11.004","article-title":"Multiple etiologies of equine recurrent uveitis\u2013A natural model for human autoimmune uveitis: A brief review","volume":"44","author":"Witkowski","year":"2016","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.156914","article-title":"Experimental autoimmune uveitis and other animal models of uveitis: An update","volume":"63","author":"Bansal","year":"2015","journal-title":"Indian J Ophthalmol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623725","article-title":"Uveitis: molecular pathogenesis and emerging therapies","volume":"12","author":"Egwuagu","year":"2021","journal-title":"Front Immunol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137020","article-title":"Microbiome in immune-mediated uveitis","volume":"23","author":"Rodriguez-Fernandez","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.2174\/1566524015666150731100318","article-title":"Mouse models of experimental autoimmune uveitis: comparative analysis of adjuvant-induced vs spontaneous models of uveitis","volume":"15","author":"Chen","year":"2015","journal-title":"Curr Mol Med"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"key":"B207","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41435-022-00168-6","article-title":"Progress in the genetics of uveitis","volume":"23","author":"Huang","year":"2022","journal-title":"Genes Immun"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)91090-8","article-title":"Acute anterior uveitis and HL-A 27","volume":"302","author":"Brewerton","year":"1973","journal-title":"Lancet"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.2174\/1566524015666150731095201","article-title":"Spontaneous ocular autoimmunity in mice expressing a transgenic T cell receptor specific to retina: A tool to dissect mechanisms of uveitis","volume":"15","author":"Horai","year":"2015","journal-title":"Curr Mol Med"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.08.002","article-title":"Targeting interleukin-6 in autoimmune uveitis","volume":"16","author":"Mesquida","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B211","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00296-017-3775-5","article-title":"Biological therapies for the treatment of Behcet\u2019s disease-related uveitis beyond TNF-alpha blockade: a narrative review","volume":"38","author":"Sota","year":"2018","journal-title":"Rheumatol Int"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179584","article-title":"CD4(+) T-cell plasticity in non-infectious retinal inflammatory disease","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B213","doi-asserted-by":"publisher","first-page":"115236","DOI":"10.1016\/j.bcp.2022.115236","article-title":"JAK-STAT signaling pathway in non-infectious uveitis","volume":"204","author":"Su","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"e29742","DOI":"10.1371\/journal.pone.0029742","article-title":"Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis","volume":"7","author":"Yu","year":"2012","journal-title":"PloS One"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01051","article-title":"Interleukin 35-producing exosomes suppress neuroinflammation and autoimmune uveitis","volume":"11","author":"Kang","year":"2020","journal-title":"Front Immunol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"16188","DOI":"10.1038\/s41598-020-73093-1","article-title":"STAT3 deficiency in B cells exacerbates uveitis by promoting expansion of pathogenic lymphocytes and suppressing regulatory B cells (Bregs) and Tregs","volume":"10","author":"Oladipupo","year":"2020","journal-title":"Sci Rep"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201848073","article-title":"Tissue-specific production of MicroRNA-155 inhibits melanocortin 5 receptor-dependent suppressor macrophages to promote experimental autoimmune uveitis","volume":"49","author":"Muhammad","year":"2019","journal-title":"Eur J Immunol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-11937","article-title":"STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis","volume":"54","author":"Escobar","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B220","doi-asserted-by":"publisher","first-page":"m4979","DOI":"10.1136\/bmj.m4979","article-title":"Uveitis for the non-ophthalmologist","volume":"372","author":"Burkholder","year":"2021","journal-title":"BMJ"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003819","article-title":"Inhibition of SOCS1-\/- lethal autoinflammatory disease correlated to enhanced peripheral Foxp3+ regulatory T cell homeostasis","volume":"187","author":"Collins","year":"2011","journal-title":"J Immunol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304144","article-title":"Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase\/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice","volume":"34","author":"Recio","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7688","article-title":"Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation","volume":"52","author":"Yu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.07.021","article-title":"Quality of life and body region affected by psoriasis: A systematic review","volume":"114","author":"Nabieva","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"B225","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/joim.13311","article-title":"Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multi-centre cohort study","volume":"290","author":"Tinggaard","year":"2021","journal-title":"J Intern Med"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.019","article-title":"Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States","volume":"86","author":"Merola","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","article-title":"US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"17","author":"Lebwohl","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"Bras Dermatol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.619502","article-title":"Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain","volume":"290","author":"Tokarski","year":"2015","journal-title":"J Biol Chem"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112399200","article-title":"Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells","volume":"277","author":"Xie","year":"2002","journal-title":"J Biol Chem"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15360","article-title":"Understanding psoriasis: the development of the immune pathogenesis","volume":"47","author":"Papadopoullos","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043391","article-title":"Tyk2 targeting in immune-mediated inflammatory diseases","volume":"24","author":"Rusinol","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B236","doi-asserted-by":"publisher","first-page":"adv00030","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and genetics","volume":"100","author":"Dand","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbz011","article-title":"Genetics of psoriasis: a basis for precision medicine","volume":"2","author":"Ran","year":"2019","journal-title":"Precis Clin Med"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13806","article-title":"Critical role of environmental factors in the pathogenesis of psoriasis","volume":"44","author":"Zeng","year":"2017","journal-title":"J Dermatol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.26444\/aaem\/112107","article-title":"Environmental risk factors and epigenetic alternations in psoriasis","volume":"27","author":"Roszkiewicz","year":"2020","journal-title":"Ann Agric Environ Med"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.06.019","article-title":"Mouse models of psoriasis: A comprehensive review","volume":"142","author":"Gangwar","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000176","article-title":"Attenuating janus kinases (JAK) by tofacitinib effectively prevented psoriasis pathology in various mouse skin inflammation models","volume":"4","author":"Ma","year":"2013","journal-title":"J Clin Cell Immunol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.06.060","article-title":"Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions","volume":"764","author":"Fukuyama","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"5021537","DOI":"10.1155\/2016\/5021537","article-title":"Tolerogenic dendritic cells generated with tofacitinib ameliorate experimental autoimmune encephalomyelitis through modulation of Th17\/Treg balance","volume":"2016","author":"Zhou","year":"2016","journal-title":"J Immunol Res"},{"key":"B244","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2340\/00015555-3086","article-title":"Antipruritic effects of Janus kinase inhibitor tofacitinib in a mouse model of psoriasis","volume":"99","author":"Hashimoto","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"B246","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B249","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B251","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"key":"B253","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605","article-title":"TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors","volume":"61","author":"Jo","year":"2022","journal-title":"Int J Dermatol"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"B257","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab135","article-title":"Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise","volume":"27","author":"Danese","year":"2021","journal-title":"Inflammation Bowel Dis"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12929","article-title":"Safety and pharmacokinetics of the oral TYK2 inhibitor PF-06826647: A phase I, randomized, double-blind, placebo-controlled, dose-escalation study","volume":"14","author":"Singh","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20111647","article-title":"New mimetic peptides of the kinase-inhibitory region (KIR) of SOCS1 through focused peptide libraries","volume":"443","author":"Doti","year":"2012","journal-title":"Biochem J"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30001-X","article-title":"The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data","volume":"6","author":"Al-Diwani","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002917","article-title":"The clinical spectrum of Caspr2 antibody-associated disease","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"B267","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9153-8","article-title":"Patient characteristics and outcome associations in AMPA receptor encephalitis","volume":"266","author":"Laurido-Soto","year":"2019","journal-title":"J Neurol"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000991","article-title":"DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients","volume":"83","author":"Tobin","year":"2014","journal-title":"Neurology"},{"key":"B271","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein igG disease vs aquaporin 4 igG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"key":"B272","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/PRA.0000000000000602","article-title":"Anti-NMDA receptor encephalitis: A challenge in psychiatric settings","volume":"28","author":"Kanniah","year":"2022","journal-title":"J Psychiatr Pract"},{"key":"B273","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.08.009","article-title":"An evolving redefinition of autoimmune encephalitis","volume":"18","author":"Esposito","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B275","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jalm\/jfab102","article-title":"Autoimmune encephalitis and autoantibodies: A review of clinical implications","volume":"7","author":"Hebert","year":"2022","journal-title":"J Appl Lab Med"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13207","article-title":"Response to immunotherapy in anti-IgLON5 disease: A systematic review","volume":"141","author":"Cabezudo-Garcia","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww208","article-title":"Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis","volume":"139","author":"Kreye","year":"2016","journal-title":"Brain"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J Neurosci"},{"key":"B281","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/cid\/cir1038","article-title":"The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project","volume":"54","author":"Gable","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25829","article-title":"NMDAR antibodies alter dopamine receptors and cause psychotic behavior in mice","volume":"88","author":"Carceles-Cordon","year":"2020","journal-title":"Ann Neurol"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14662","article-title":"A mouse model of seizures in anti-N-methyl-d-aspartate receptor encephalitis","volume":"60","author":"Taraschenko","year":"2019","journal-title":"Epilepsia"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80792","article-title":"Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells","volume":"126","author":"Dileepan","year":"2016","journal-title":"J Clin Invest."},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1911097117","article-title":"Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis","volume":"117","author":"Platt","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16848","article-title":"Tofacitinib treatment for refractory autoimmune encephalitis","volume":"62","author":"Jang","year":"2021","journal-title":"Epilepsia"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00943-z","article-title":"Treatment options in refractory autoimmune encephalitis","volume":"36","author":"Dinoto","year":"2022","journal-title":"CNS Drugs"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24195","article-title":"Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis","volume":"76","author":"Moscato","year":"2014","journal-title":"Ann Neurol"},{"key":"B289","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1212\/NXI.0000000000000075","article-title":"Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis","volume":"2","author":"Kortvelyessy","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1177672","article-title":"Optimizing animal models of autoimmune encephalitis using active immunization","volume":"14","author":"Linnoila","year":"2023","journal-title":"Front Immunol"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.05.026","article-title":"Surgical outcomes in patients with anti-N-methyl D-aspartate receptor encephalitis with ovarian teratoma","volume":"221","author":"Dai","year":"2019","journal-title":"Am J Obstet Gynecol."},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"B293","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2021.04.001","article-title":"Pediatric autoimmune encephalitis and its relationship with infection","volume":"120","author":"Li","year":"2021","journal-title":"Pediatr Neurol"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25655","article-title":"Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1\/CASPR2 epilepsy","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"B295","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1186\/s13063-020-04516-7","article-title":"Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis","volume":"21","author":"Wickel","year":"2020","journal-title":"Trials"},{"key":"B296","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40120-022-00327-x","article-title":"Low recruitment in a double-blind, placebo-controlled trial of ocrelizumab for autoimmune encephalitis: A case series and review of lessons learned","volume":"11","author":"Blackburn","year":"2022","journal-title":"Neurol Ther"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol"},{"key":"B298","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790962","article-title":"Immunotherapy for refractory autoimmune encephalitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"B301","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/ar3465","article-title":"Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models","volume":"13","author":"Pathak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg255","article-title":"Cytokine balance in kidney tissue from lupus nephritis patients","volume":"42","author":"Uhm","year":"2003","journal-title":"Rheumatol (Oxford)."},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-013-8403-x","article-title":"Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review","volume":"47","author":"Kuhn","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn246","article-title":"Autoimmune diseases: insights from genome-wide association studies","volume":"17","author":"Lettre","year":"2008","journal-title":"Hum Mol Genet"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1086\/428480","article-title":"Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus","volume":"76","author":"Sigurdsson","year":"2005","journal-title":"Am J Hum Genet"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1517\/14728220903196761","article-title":"Targeting the CXCR4\/CXCL12 axis in systemic lupus erythematosus","volume":"13","author":"Chong","year":"2009","journal-title":"Expert Opin Ther Targets."},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0801920","article-title":"CXCR4\/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus","volume":"182","author":"Wang","year":"2009","journal-title":"J Immunol"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.13.13.1699","article-title":"The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK\/STAT pathway","volume":"13","author":"Vila-Coro","year":"1999","journal-title":"FASEB J"},{"key":"B309","doi-asserted-by":"publisher","first-page":"e000199","DOI":"10.1136\/lupus-2016-000199","article-title":"Mouse models of lupus: what they tell us and what they don\u2019t","volume":"5","author":"Richard","year":"2018","journal-title":"Lupus Sci Med"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1385\/IR:25:2:143","article-title":"Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL\/lpr mice","volume":"25","author":"Reilly","year":"2002","journal-title":"Immunol Res"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.107","article-title":"Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model","volume":"135","author":"Chan","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B312","doi-asserted-by":"publisher","first-page":"988","DOI":"10.4049\/jimmunol.1103031","article-title":"Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis","volume":"189","author":"Berthier","year":"2012","journal-title":"J Immunol"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B314","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12865-017-0225-9","article-title":"JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation","volume":"18","author":"Ikeda","year":"2017","journal-title":"BMC Immunol"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675542","article-title":"Tofacitinib ameliorates lupus through suppression of T cell activation mediated by TGF-beta type I receptor","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"key":"B316","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.704526","article-title":"Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"key":"B317","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"B318","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315573347","article-title":"DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184","volume":"24","author":"van Vollenhoven","year":"2015","journal-title":"Lupus"},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"key":"B320","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.09.030","article-title":"Oral tofacitinib citrate for recalcitrant cutaneous lupus","volume":"20","author":"Bonnardeaux","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"B323","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222335","article-title":"Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus","volume":"81","author":"Dorner","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B324","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216571","article-title":"Efficacy of JAK 1\/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus","volume":"79","author":"Maeshima","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B325","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2022","journal-title":"Rheumatol (Oxford)."},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001490","article-title":"Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy","volume":"6","author":"Baker","year":"2020","journal-title":"RMD Open"},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: first approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13146","article-title":"Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials","volume":"15","author":"Muensterman","year":"2022","journal-title":"Clin Transl Sci"},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/hkokxs","article-title":"Resolution of accelerated nodulosis with upadacitinib in a patient with systemic lupus erythematosus and Jaccoud\u2019s arthropathy","volume":"135","author":"Michailidou","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B331","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B332","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"B333","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B334","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-014-0309-2","article-title":"Decreased SOCS1 mRNA expression levels in peripheral blood mononuclear cells from patients with systemic lupus erythematosus in a Chinese population","volume":"15","author":"Qiu","year":"2015","journal-title":"Clin Exp Med"},{"key":"B335","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-7347.2011.02.003","article-title":"Activation of JAK-STAT1 signal transduction pathway in lesional skin and monocytes from patients with systemic lupus erythematosus","volume":"36","author":"Li","year":"2011","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban."},{"key":"B336","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/sji.12475","article-title":"Therapeutic potential for targeting the suppressor of cytokine signalling-1 pathway for the treatment of SLE","volume":"84","author":"Sukka-Ganesh","year":"2016","journal-title":"Scand J Immunol"},{"key":"B337","doi-asserted-by":"publisher","first-page":"109615","DOI":"10.1016\/j.cellsig.2020.109615","article-title":"Inhibition of suppressor of cytokine signaling 1 mediates the profibrotic effect of TWEAK\/Fn14 signaling on kidney cells","volume":"71","author":"Chen","year":"2020","journal-title":"Cell Signal"},{"key":"B338","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B339","article-title":"Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits."},{"key":"B340","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S287218","article-title":"The effectiveness of ruxolitinib for acute\/chronic graft-versus-host disease in children: A retrospective study","volume":"15","author":"Yang","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B341","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"},{"key":"B342","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J Med Chem"},{"key":"B343","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25153321","article-title":"Inside perspective of the synthetic and computational toolbox of JAK inhibitors: recent updates","volume":"25","author":"Coricello","year":"2020","journal-title":"Molecules"},{"key":"B344","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2038134","article-title":"Tofacitinib for the treatment of active ankylosing spondylitis in adults","volume":"18","author":"Mohanakrishnan","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B345","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"B346","volume-title":"FDA Fact Sheet for Healthcare Providers Emergency use Authorization (EUA) of Baricitinib [press release]","year":"2022"},{"key":"B347","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"B348","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01131-y","article-title":"Peficitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B349","volume-title":"U.S. FDA approves RINVOQ","year":"2022"},{"key":"B350","volume-title":"RINVOQ","year":"2022"},{"key":"B351","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B352","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B353","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B354","volume-title":"FDA approves drug for adults with rare form of bone marrow disorder [press release]","year":"2022"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1271102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T18:18:01Z","timestamp":1698344281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1271102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":354,"alternative-id":["10.3389\/fimmu.2023.1271102"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1271102","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"article-number":"1271102"}}